RANBP6 Antibody

What is RANBP6 and what cellular functions does it perform?

RANBP6 is a member of the importin β family that functions in nuclear protein import as a nuclear transport receptor. According to research published in Nature Communications, RANBP6 plays a critical role in regulating EGFR (epidermal growth factor receptor) signaling through a sophisticated mechanism involving STAT3 (signal transducer and activator of transcription 3) . RANBP6 facilitates the nuclear translocation of STAT3, which then binds to the EGFR promoter and represses EGFR transcription. The protein has a calculated molecular weight of approximately 125 kDa and contains 1105 amino acids .

RANBP6 has been detected in various tissues and cell lines, including:

• Human cell lines: HEK-293, HeLa

• Mouse tissues: Skeletal muscle, testis

• Mouse cell lines: NIH/3T3

• Rat tissues: Testis

This wide distribution suggests that RANBP6 plays a fundamental role in cellular physiology across different tissues and species.

Most commercially available RANBP6 antibodies show reactivity with:

• Human

• Mouse

• Rat

For example, Proteintech's RANBP6 antibody (17656-1-AP) has been tested and confirmed to react with samples from all three species in Western blot applications . Similarly, Boster Bio's Anti-Ran-binding protein 6 RANBP6 Antibody (A15427-2) is reactive with human, mouse, and rat samples .

When planning experiments involving other species, researchers should verify the cross-reactivity of their selected antibody or consider using species-specific antibodies if available.

How does RANBP6 regulate EGFR signaling pathways?

RANBP6 regulates EGFR signaling through a multi-step mechanism involving STAT3 nuclear translocation and transcriptional repression:

• RANBP6, as an importin β family member, facilitates the nuclear import of STAT3

• Nuclear STAT3 binds to the EGFR promoter and represses its transcription

• When RANBP6 is silenced, STAT3 nuclear translocation is impaired

• Reduced nuclear STAT3 leads to derepression of EGFR transcription

• This results in increased EGFR mRNA and protein levels

• Higher EGFR levels enhance EGFR signaling pathway output

Experimental evidence shows that RanBP6 knockdown typically increases EGFR mRNA levels approximately two-fold, while complete RanBP6 depletion using CRISPR/Cas9 results in even more pronounced elevation of EGFR mRNA and protein levels . Additionally, RanBP6 knockdown increases the expression of a luciferase reporter cloned downstream of the EGFR promoter sequence but has no effect on a control β-actin luciferase reporter, suggesting that RanBP6 specifically regulates EGFR RNA levels through effects on EGFR promoter activity .

What is the connection between RANBP6 and glioblastoma?

Research has revealed a significant connection between RANBP6 and glioblastoma (GBM):

• Focal deletions of the RanBP6 locus on chromosome 9p have been found in a subset of glioblastoma patients

• Silencing of RanBP6 promotes glioma growth in vivo through upregulation of EGFR expression

• Cells derived from RanBP6 knockdown tumors show increased Egfr mRNA levels

• Xenografting human glioma cell lines with reconstituted RanBP6 into mice leads to reduced tumor growth

This connection provides evidence for a novel mechanism of EGFR deregulation in cancer through silencing of components of the nuclear import pathway. The findings suggest that RanBP6 may serve as a tumor suppressor in GBM, and its loss contributes to increased EGFR signaling and enhanced tumor growth .

How can researchers interpret contradictory results when studying RANBP6 in different experimental systems?

When faced with contradictory results regarding RANBP6 function or expression across different experimental systems, researchers should consider several factors:

• Cell/tissue-specific effects: RANBP6 may have context-dependent functions. For example, its role in EGFR regulation might be more pronounced in cells with high EGFR expression.

• Experimental approach differences: Various knockdown techniques (siRNA, shRNA, CRISPR) may have different efficiencies and off-target effects. Complete depletion of RANBP6 using CRISPR/Cas9 has been shown to result in more pronounced effects on EGFR expression compared to partial knockdown .

• Interacting partners: The function of RANBP6 depends on its interaction with other proteins. Variations in the expression levels of these partners (e.g., STAT3) across different cell types might influence experimental outcomes.

• Antibody specificity issues: When contradictory results arise from immunodetection studies, consider antibody validation status. Some antibodies have been verified on protein arrays containing the target protein plus 383 other non-specific proteins .

• Analysis methods: Different computational workflows for data analysis (particularly for RNA-Seq data) can lead to contradictory interpretations. As noted in search result , many existing algorithms were found to be ill-suited for predicting certain biological phenomena, necessitating the development of novel computational workflows for accurate prediction .

To resolve contradictions, researchers should implement multiple approaches (e.g., different antibodies targeting distinct epitopes of RANBP6) and include appropriate controls to validate their findings.

What are the optimal protocols for using RANBP6 antibodies in Western blot analyses?

Based on the search results, here is an optimized protocol for Western blot analysis using RANBP6 antibodies:

Sample Preparation:

• Extract proteins from cells or tissues using RIPA buffer supplemented with protease inhibitors

• Determine protein concentration using BCA or Bradford assay

• Prepare 20-50 μg of protein per lane with reducing sample buffer

• Heat samples at 95°C for 5 minutes

Gel Electrophoresis and Transfer:

• Use 8-10% SDS-PAGE gel (RANBP6 has a molecular weight of approximately 125 kDa)

• Run the gel at 100V until the dye front reaches the bottom

• Transfer proteins to PVDF membrane (recommended for high molecular weight proteins)

Antibody Incubation:

• Block membrane with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with primary RANBP6 antibody at recommended dilution:

  • Proteintech (17656-1-AP): 1:1000-1:8000

  • Boster Bio (A15427-2): 1:500-1:1000

• Incubate overnight at 4°C with gentle rocking

• Wash 3x with TBST, 5 minutes each

• Incubate with appropriate HRP-conjugated secondary antibody for 1 hour at room temperature

• Wash 3x with TBST, 5 minutes each

• Develop using ECL substrate and image

Expected Results:

• RANBP6 should be detected at approximately 125 kDa

• Positive controls include HEK-293 cells, HeLa cells, and NIH/3T3 cells

Note that specific protocol details may need to be optimized based on your experimental system and the specific antibody being used.

What controls should be included when using RANBP6 antibodies in experimental designs?

When designing experiments using RANBP6 antibodies, include the following controls to ensure experimental validity:

Positive Controls:

• Cell lines known to express RANBP6:

  • HEK-293 cells

  • HeLa cells

  • NIH/3T3 cells

  • Mouse skeletal muscle tissue

  • Mouse or rat testis tissue

Negative Controls:

• RANBP6 knockdown or knockout samples (using siRNA or CRISPR/Cas9)

• Isotype control antibody (same species and isotype as the RANBP6 antibody)

• Secondary antibody only (omit primary antibody)

Validation Controls:

• Peptide competition assay (pre-incubation of antibody with immunizing peptide)

• Multiple antibodies targeting different epitopes of RANBP6

• Recombinant RANBP6 protein as a reference standard

Application-Specific Controls:

• For immunoprecipitation: Input sample, IgG control

• For immunofluorescence: Counterstain with DAPI to visualize nuclei and confirm subcellular localization

• For Western blot: Loading control (e.g., β-actin, GAPDH) to normalize protein expression

The specificity of some RANBP6 antibodies has been verified on protein arrays containing the target protein plus 383 other non-specific proteins, providing high confidence in antibody specificity .

How can researchers optimize RANBP6 antibody usage in immunofluorescence studies examining STAT3 nuclear translocation?

For immunofluorescence studies examining RANBP6's role in STAT3 nuclear translocation, consider these optimization strategies:

Antibody Selection and Validation:

• Choose antibodies with validated immunofluorescence applications

• Verify specificity using RANBP6 knockdown controls

• Select antibodies raised in different host species for co-staining (e.g., rabbit anti-RANBP6 and mouse anti-STAT3)

Sample Preparation:

• Test different fixation methods: 4% paraformaldehyde (10-15 minutes) works well for most nuclear proteins

• Optimize permeabilization: 0.1-0.5% Triton X-100 for nuclear proteins

• Consider using nuclear extraction protocols to enrich for nuclear proteins when studying translocation events

Staining Protocol:

• Block with 5% normal serum from the species of secondary antibody

• Use recommended antibody dilutions for immunofluorescence:

  • Novus Biologicals (NBP2-55826): 1-4 μg/ml

  • Proteintech (17656-1-AP): 1:50-1:500

  • Sigma-Aldrich (HPA043748): 0.25-2 μg/ml

• Incubate primary antibodies overnight at 4°C

• Use fluorophore-conjugated secondary antibodies with minimal spectral overlap

• Include DAPI or Hoechst staining to visualize nuclei

Analysis of STAT3 Translocation:

• Capture z-stack images to ensure complete visualization of nuclear localization

• Perform quantitative image analysis to measure nuclear/cytoplasmic STAT3 ratios

• Compare STAT3 localization in control vs. RANBP6-depleted cells

• Track STAT3 localization kinetics following pathway activation (e.g., by EGF stimulation)

Experimental Design:

• Include time-course experiments to capture dynamic translocation events

• Compare conditions with and without pathway activation

• Consider using stimuli known to activate STAT3 (e.g., IL-6, EGF)

• Include appropriate positive controls (e.g., cells with constitutively active STAT3)

This optimized approach should allow researchers to accurately assess the role of RANBP6 in STAT3 nuclear translocation and its subsequent effects on EGFR regulation.

How can researchers troubleshoot weak or non-specific RANBP6 antibody signals?

When encountering weak or non-specific signals with RANBP6 antibodies, systematically address the following aspects:

For Weak Signals:

• Antibody concentration: Increase primary antibody concentration within recommended ranges:

  • For WB: Try 1:500 instead of 1:1000

  • For IF/ICC: Try 1:50 instead of 1:200

• Exposure/incubation time:

  • Extend primary antibody incubation from overnight to 24-48 hours at 4°C

  • For WB: Increase ECL exposure time or use more sensitive substrates

  • For IF: Increase exposure time or detector gain (without introducing artifacts)

• Sample preparation:

  • Ensure adequate protein concentration

  • Try different lysis buffers (RIPA vs. NP-40)

  • For nuclear proteins, consider using nuclear extraction protocols

  • For IF/IHC: Test different antigen retrieval methods

• Detection system:

  • Use signal amplification systems (e.g., biotin-streptavidin)

  • Try more sensitive secondary antibodies

  • For fluorescence detection, use brighter fluorophores

For Non-specific Signals:

• Blocking optimization:

  • Increase blocking time (2-3 hours instead of 1 hour)

  • Try different blocking agents (BSA vs. normal serum vs. commercial blockers)

  • Add 0.1-0.3% Triton X-100 to reduce hydrophobic interactions

• Washing steps:

  • Increase washing duration and number of washes

  • Use higher salt concentration in wash buffer (150-300 mM NaCl)

  • Add 0.05-0.1% Tween-20 to wash buffer

• Antibody validation:

  • Test antibody specificity in RANBP6 knockdown/knockout samples

  • Perform peptide competition assays

  • Try different antibodies targeting different epitopes of RANBP6

• Cross-reactivity control:

  • Use proper negative controls (isotype control, secondary antibody only)

  • Pre-adsorb antibody with tissue/cell lysate from species not expected to cross-react

Remember that storage conditions are critical for antibody performance. Store antibodies according to manufacturer recommendations, typically at -20°C with minimal freeze-thaw cycles .

How can researchers analyze RANBP6-dependent changes in EGFR expression and signaling?

To comprehensively analyze RANBP6-dependent changes in EGFR expression and signaling, researchers should implement multiple complementary approaches:

1. Transcriptional Analysis:

• Quantitative RT-PCR to measure EGFR mRNA levels following RANBP6 knockdown/overexpression

• Luciferase reporter assays using EGFR promoter constructs to directly assess transcriptional regulation

• ChIP assays to measure STAT3 binding to the EGFR promoter in the presence/absence of RANBP6

2. Protein Expression Analysis:

• Western blot to quantify total EGFR protein levels

• Flow cytometry to measure cell surface EGFR levels

• Immunofluorescence to visualize EGFR localization and expression patterns

3. Signaling Pathway Activation:

• Western blot for phosphorylated EGFR and downstream effectors (ERK, AKT, STAT3)

• Phospho-kinase arrays to assess multiple pathway components simultaneously

• Kinase activity assays to measure functional activation

4. Functional Assays:

• Cell proliferation assays to measure EGFR-dependent growth

• Migration/invasion assays to assess EGFR-mediated motility

• Drug sensitivity assays using EGFR inhibitors to determine pathway dependence

5. Systems-Level Analysis:

• RNA-Seq to identify global transcriptional changes

• Phosphoproteomics to comprehensively profile signaling alterations

• Gene set enrichment analysis (GSEA) to identify affected pathways

Data Integration and Interpretation:

• Compare acute vs. chronic RANBP6 depletion effects

• Analyze dose-dependent relationships between RANBP6 levels and EGFR expression

• Correlate findings across multiple cell types and experimental systems

• Consider context-dependent effects (e.g., basal vs. stimulated conditions)

Research has shown that RanBP6 knockdown reduces the expression of STAT3 reporter genes and affects the enrichment scores of STAT3-regulated gene sets, with gene sets activated by STAT3 showing lower enrichment scores and gene sets negatively regulated by STAT3 showing higher enrichment scores in RanBP6 knockdown cells .

How can RANBP6 antibodies be used to investigate potential therapeutic targets in glioblastoma?

RANBP6 antibodies can be instrumental in exploring therapeutic opportunities in glioblastoma through several research applications:

1. Patient Stratification and Biomarker Development:

• Immunohistochemical analysis of RANBP6 expression in GBM patient samples

• Correlation of RANBP6 levels with EGFR expression, tumor grade, and patient outcomes

• Development of RANBP6 as a predictive biomarker for EGFR-targeted therapies

2. Mechanism-Based Drug Discovery:

• High-content screening using RANBP6 and EGFR dual staining to identify compounds that restore normal RANBP6-EGFR regulation

• Evaluation of compounds that enhance nuclear import of STAT3 in RANBP6-deficient cells

• Development of proteolysis targeting chimeras (PROTACs) for selective degradation of elevated EGFR in RANBP6-deficient GBM

3. Combination Therapy Strategies:

• Assessment of RANBP6 status as a determinant of sensitivity to EGFR inhibitors

• Identification of synthetic lethal interactions in RANBP6-deficient GBM cells

• Evaluation of combinations targeting both EGFR and compensatory pathways activated in RANBP6-deficient contexts

4. Preclinical Model Development:

• Generation and characterization of RANBP6 knockout GBM organoids

• Creation of patient-derived xenografts from RANBP6-deficient GBM tumors

• Development of inducible RANBP6 expression systems to study therapeutic rescue effects

5. Mechanistic Studies:

• Investigation of nuclear import pathways as therapeutic targets in GBM

• Analysis of the broader impact of nuclear transport disruption on cancer cell signaling

• Evaluation of RANBP6 restoration as a therapeutic strategy

Research has demonstrated that silencing of RanBP6 promotes glioma growth in vivo through upregulation of EGFR expression, while xenografting human glioma cell lines with reconstituted RanBP6 leads to reduced tumor growth . These findings suggest that strategies to restore RANBP6 function or counteract its loss could represent novel therapeutic approaches for GBM.

What methodological considerations should be addressed when analyzing RNA-Seq data to study RANBP6-regulated gene expression?

When analyzing RNA-Seq data to study RANBP6-regulated gene expression, researchers should consider several methodological aspects to ensure robust and reliable results:

1. Experimental Design Considerations:

• Include multiple biological replicates (minimum 3-4 per condition)

• Control for confounding variables (cell density, passage number, batch effects)

• Include appropriate controls (empty vector, non-targeting shRNA)

• Consider time-course experiments to capture dynamic gene expression changes

2. Library Preparation and Sequencing:

• Account for RNA integrity when comparing samples

• Maintain consistent sequencing depth across samples

• Consider strand-specific sequencing to detect antisense transcription

• Use appropriate RNA isolation methods based on target transcripts (total RNA vs. polyA selection)

3. Data Processing and Quality Control:

• Address multi-mapping reads that may map equally well to multiple genomic locations

• Perform appropriate normalization for sequencing depth

• Use negative binomial distributions rather than Poisson statistics to account for biological variability

• Apply batch correction methods if necessary

4. Differential Expression Analysis:

• Select appropriate statistical models for RNA-Seq data

• Account for biological variability in statistical testing

• Apply multiple testing correction for false discovery rate control

• Validate key findings using orthogonal methods (qRT-PCR, protein analysis)

5. Pathway and Functional Analysis:

• Use appropriate gene set collections relevant to RANBP6 and EGFR biology

• Apply single-sample gene set enrichment analysis (ssGSEA) to evaluate STAT3 target genes

• Consider the directionality of gene regulation (up vs. down-regulated)

• Integrate with protein interaction data to identify regulatory networks

6. Validation and Interpretation:

• Validate key target genes at protein level

• Correlate findings with functional assays

• Consider context-dependent effects

• Account for potential discrepancies between transcriptional and translational regulation

As noted in the search results, DESeq and other RNA-Seq analysis pipelines that utilize negative binomial distributions are recommended as they allow for the incorporation of "extra variance" and estimation of biological variability from the data itself . Researchers should be aware that different computational workflows can lead to different interpretations, particularly when studying novel regulatory mechanisms.

Concluding Remarks

Research on RANBP6 antibodies and their applications in studying the functional role of this protein has provided significant insights into EGFR regulation and cancer biology, particularly in glioblastoma. The mechanism whereby RANBP6 regulates EGFR expression through facilitating STAT3 nuclear translocation represents a novel pathway that connects nuclear transport machinery to oncogenic signaling.

As research in this field progresses, continued refinement of antibody-based detection methods and experimental protocols will enable more detailed characterization of RANBP6 functions in normal physiology and disease. Researchers should remain attentive to antibody validation, appropriate experimental controls, and integration of multiple methodological approaches to generate robust and reproducible data.